Munich Long COVID Registry for Children, Adolescents, and Adults
ConditionPost-COVID Condition
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorTechnical University of Munich
About this trial
The MLC-R aims to create a large-scale registry that provides data on epidemiology, phenotypes, and disease trajectories of and health care for Long COVID at any age in Germany, which can be used for future clinical trials.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Any subsequent medical data that question the diagnosis of PCC or post-COVIDvac condition
Clinical picture can be explained by another underlying disease.
Pregnancy
Trial population
Patients with PCC
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Phenotyping of Post-COVID condition: Medical History
Routine assessment of the medical history, such as current and previous medication, vaccinations, comorbidities, and more, to achieve a profound and detailed Post-COVID condition phenotype.
Time frame
5 years2
Phenotyping of Post-COVID condition: Physical Examination
Routine physical examination to achieve a profound and detailed Post-COVID condition phenotype.
Time frame
5 years3
Phenotyping of Post-COVID condition: Laboratory Parameters
Measurement of a routine set of laboratory parameters including blood tests (cell count, C-reactive protein, organ function, immunoglobulins, antibodies, etc.) and urine/stool analysis (calprotectin, blood) to achieve a profound Post-COVID condition phenotype.
Time frame
5 years4
Phenotyping of Post-COVID condition: Functional Tests
Technical exams (e.g. pulmonary function tests, electrocardiography, ultrasound, magnetic resonance imaging, etc.) will be performed as indicated to achieve a profound and detailed Post-COVID condition phenotype.
Time frame
5 yearsSecondary outcomes
1
Analyzation of numbers of physicians involved
Patients' journeys will be analyzed in terms of the number of physicians involved
Time frame
5 years2
Evaluation of kind of spezializations of physicians involved
Patients' journeys will be analyzed in terms of the kind of specializations of physicians involved
Time frame
5 years3
Evaluation of kind of the latency of symptoms
Patients' journeys will be analyzed in terms of the kind of specializations of physicians involved
Time frame
5 years4
Evaluation of kind of the onset of therapy
Patients' journeys will be analyzed in terms of the latency from symptom onset to initiation of therapy in months.
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Technical University of Munich
Lead sponsor
Charite University, Berlin, Germany
Collaborator
Ruhr University of Bochum
Collaborator
Technische Universität Dresden
Collaborator
University of Freiburg
Collaborator
University of Hamburg-Eppendorf
Collaborator
Leipniz University Hannover, Germany.
Collaborator
Saarland University Homburg,Germany.
Collaborator
University of Jena
Collaborator
University of Kassel, Germany.
Collaborator
University of Cologne
Collaborator
Source ClinicalTrials.gov